Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972694 · ClinicalTrials.gov registry record · NA
Effect of Grapes in Inflammatory Bowel Disease
A NA study of Crohn Disease, sponsored by Case Western Reserve University.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT05972694: Completed NA study of Crohn Disease, sponsored by Case Western Reserve University.
NCT05972694 is a NA study of Crohn Disease that has completed, run by Case Western Reserve University. The registered enrollment target is 21 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05972694, a NA study of Crohn Disease, has completed, sponsored by Case Western Reserve University.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of this pilot intervention study is to determine the impact of grape powder (46g/day freeze dried whole grape powder provided by the California Table Grape Commission) on the gut microbiotacomposition in adult patients with the IBD subtype Crohn's disease (CD).
Primary Outcome
16S microbiome
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Freeze dried grape powder
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-02-15 |
| Phase | NA |
What the finished NCT05972694 record still lists
NCT05972694 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 1 intervention - of which Freeze dried grape powder is the first listed.
NCT05972694 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05972694 about?
NCT05972694 is a clinical study titled "Effect of Grapes in Inflammatory Bowel Disease". The overall objective of this pilot intervention study is to determine the impact of grape powder (46g/day freeze dried whole grape powder provided by the California Table Grape Commission) on the gut microbiotacomposition in adult patients with the IBD subtype Crohn's disease (CD).
What is the current status of trial NCT05972694?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2024-09-16. Estimated completion is 2026-02-15.
What conditions does trial NCT05972694 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT05972694?
The interventions under investigation include: Freeze dried grape powder (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05972694?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05972694 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05972694's enrollment target sits among peer trials
21 61st of 71 higher than 10 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
RECRUITING · NA
-
Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility
RECRUITING · NA
-
Impact of Prebiotics in Ulcerative Colitis
RECRUITING · NA
-
RISE: A Remote Study of Insomnia Treatment in Crohn's Disease
RECRUITING · NA
-
A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI